SGLT2 inhibitors for the treatment of diabetes: a patent review (2019-23)
{{output}}
Introduction: The sodium-glucose co-transporter 2 (SGLT2) inhibitors are FDA-approved class of drugs for diabetes management. They improve glycemic control by inducing glucosuria. Notwithstanding with potent anti-hyperglycemic ac... ...
